Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 29

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 29
---
 underwriting fees 
     -  
     -  
     -  
     -  
     5,690,000  
     -  
     -  
     5,690,000 
  
    Reclassification of earnout liability 
     -  
     -  
     -  
     -  
     (4,900,000) 
     -  
     -  
     (4,900,000)
  
    Conversion of CERo bridge notes and accrued interest into Series A preferred stock 
     630  
     627,154  
     -  
     -  
     -  
     -  
     -  
     627,154 
  
    Conversion of working capital loan into Series A preferred stock 
     1,605  
     1,555,000  
     -  
     -  
     -  
     -  
     -  
     1,555,000 
  
    Issuance of Series A shares sold to investors, net 
     7,854  
     6,755,698  
     -  
     -  
     (856,663) 
     -  
     -  
     5,899,035 
  
    Issuance of Series A Preferred Warrants 
     -  
     -  
     -  
     -  
     2,000,000  
     (2,000,000) 
     -  
     - 
  
    Issuance of common stock to Keystone Capital LLC for equity line of credit 
     -  
     -  
     59  
     -  
     633,345  
     -  
     -  
     633,345 
  
    Opening Equity at February 14, 2024 (Successor) 
     10,089  
    $8,937,852  
     7,266  
    $1  
    $53,899,885  
    $(2,000,000) 
    $(63,185,641) 
    $(2,347,903)

12

NOTE 4 – NET LOSS PER SHARE OF